Provention Bio, Inc. Common Stock
PRVB
PRVB was delisted on the 26th of April, 2023.
63 hedge funds and large institutions have $96.2M invested in Provention Bio, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 20 increasing their positions, 17 reducing their positions, and 16 closing their positions.
38% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 16
33% more call options, than puts
Call options by funds: $1.83M | Put options by funds: $1.38M
18% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 17
5% more funds holding
Funds holding: 60 → 63 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
27% less capital invested
Capital invested by funds: $131M → $96.2M (-$34.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$6.99M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$4.57M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.14M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.04M |
| 5 |
EGI
EAM Global Investors
Solana Beach,
California
|
+$1.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$1.46M |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
-$1.33M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1.31M |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$1.05M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$1.02M |
PRVB Hedge Fund Activity: Q1 2020 in Review
63 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q1 2020, worth a combined $96.2M — down 27% from $131M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new PRVB positions and 16 closed out — a net gain of 6 holders — while 20 added to existing stakes and 17 trimmed.
The largest buyer was Millennium Management, adding an estimated $6.99M. The largest seller was Qube Research & Technologies (QRT), cutting an estimated $1.46M.
- 63 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q1 2020, up from 60 in Q4 2019.
- Funds reported $96.2M of Provention Bio, Inc. Common Stock stock for Q1 2020, down 27% quarter-over-quarter.
- 22 funds opened new Provention Bio, Inc. Common Stock positions in Q1 2020 and 16 closed out, a net change of +6 holders.
- The largest Provention Bio, Inc. Common Stock buyer in Q1 2020 was Millennium Management, an estimated $6.99M added.
- The largest Provention Bio, Inc. Common Stock seller in Q1 2020 was Qube Research & Technologies (QRT), an estimated $1.46M sold.
Based on aggregated 13F filings for Q1 2020.